Generation and testing of clinical-grade exosomes for pancreatic cancer.

Exosomes are extracellular vesicles produced by all cells with a remarkable ability to efficiently transfer genetic material, including exogenously loaded siRNA, to cancer cells. Here, we report on a bioreactor-based, large-scale production of clinical-grade exosomes employing good manufacturing practice (GMP) standards. A standard operating procedure was established to generate engineered exosomes with the ability to target oncogenic Kras (iExosomes). The clinical-grade GMP iExosomes were tested in multiple in vitro and in vivo studies to confirm suppression of oncogenic Kras and an increase in the survival of several mouse models with pancreatic cancer. We perform studies to determine the shelf life, biodistribution, toxicology profile, and efficacy in combination with chemotherapy to inform future clinical testing of GMP iExosomes. Collectively, this report illustrates the process and feasibility of generating clinical-grade exosomes for various therapies of human diseases.

[1]  R. Rahbarghazi,et al.  Exosomes and their Application in Biomedical Field: Difficulties and Advantages , 2018, Molecular Neurobiology.

[2]  Thomas D. Schmittgen,et al.  Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells , 2017, Journal of extracellular vesicles.

[3]  Mario Gimona,et al.  Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use , 2017, International journal of molecular sciences.

[4]  Róisín M. Dwyer,et al.  Engineering Exosomes for Cancer Therapy , 2017, International journal of molecular sciences.

[5]  Raghu Kalluri,et al.  Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer , 2017, Nature.

[6]  M. Gimona,et al.  A Good Manufacturing Practice-grade standard protocol for exclusively human mesenchymal stromal cell-derived extracellular vesicles. , 2017, Cytotherapy.

[7]  Raghu Kalluri,et al.  The biology and function of exosomes in cancer. , 2016, The Journal of clinical investigation.

[8]  Venkatareddy Nadithe,et al.  Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges , 2016, Acta pharmaceutica Sinica. B.

[9]  Dang Xitong,et al.  Targeted therapeutic delivery using engineered exosomes and its applications in cardiovascular diseases. , 2016, Gene.

[10]  V. LeBleu,et al.  EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.

[11]  I. Nakase,et al.  Active macropinocytosis induction by stimulation of epidermal growth factor receptor and oncogenic Ras expression potentiates cellular uptake efficacy of exosomes , 2015, Scientific Reports.

[12]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[13]  Robert Langer,et al.  Small RNA combination therapy for lung cancer , 2014, Proceedings of the National Academy of Sciences.

[14]  J. Cooper,et al.  Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice , 2014, Movement disorders : official journal of the Movement Disorder Society.

[15]  Clotilde Théry,et al.  Biogenesis and secretion of exosomes. , 2014, Current opinion in cell biology.

[16]  Meg Duroux,et al.  A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. , 2014, Biochimica et biophysica acta.

[17]  M. Epple,et al.  MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease , 2014, Leukemia.

[18]  Christian M. Metallo,et al.  Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells , 2013, Nature.

[19]  J. Leonard,et al.  FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver , 2013, Pharmaceuticals.

[20]  Imre Mäger,et al.  Extracellular vesicles: biology and emerging therapeutic opportunities , 2013, Nature Reviews Drug Discovery.

[21]  C. Coch,et al.  Exosomes as nucleic acid nanocarriers. , 2013, Advanced drug delivery reviews.

[22]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .

[23]  I. Sargent,et al.  Exosome-mediated delivery of siRNA in vitro and in vivo , 2012, Nature Protocols.

[24]  J. Marshall,et al.  Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials , 2012, PloS one.

[25]  Julian Downward,et al.  Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies , 2012, Cell Research.

[26]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[27]  Lynette M. Smith,et al.  Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin , 2011, British Journal of Cancer.

[28]  A. Hajri,et al.  K‐ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment , 2007, Cancer science.

[29]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Claes Wahlestedt,et al.  A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites , 2005, Nucleic acids research.

[31]  J. Le Pecq,et al.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer , 2005, Journal of Translational Medicine.

[32]  Mark E. Davis,et al.  Lack of interferon response in animals to naked siRNAs , 2004, Nature Biotechnology.

[33]  D. Patel,et al.  Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain , 2004, Nature.

[34]  Peter J. Cullen,et al.  Integration of calcium and RAS signalling , 2002, Nature Reviews Molecular Cell Biology.

[35]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .